Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company is expected to see a significant increase in gross margin due to rising gold prices, with a forecasted gross margin of 30% in 2025 [3][10] - The adjustment in the franchise business is anticipated to reach its conclusion in 2026, which will alleviate revenue pressure from franchise operations [10] - The company has adjusted its earnings forecast for 2025-2027, projecting earnings per share of 1.02, 1.15, and 1.27 yuan respectively, with a target price of 17.25 yuan based on a 15x PE valuation for 2026 [3][11] Financial Summary - Revenue is projected to decline from 16,290 million yuan in 2023 to 9,205 million yuan in 2025, before recovering to 11,092 million yuan by 2027, reflecting a growth rate of -33.7% in 2025 and 10.6% in 2027 [4][13] - Operating profit is expected to decrease from 1,695 million yuan in 2023 to 1,400 million yuan in 2025, with a recovery to 1,768 million yuan by 2027 [4][13] - Net profit attributable to the parent company is forecasted to decline from 1,316 million yuan in 2023 to 1,107 million yuan in 2025, before increasing to 1,379 million yuan in 2027 [4][13] - The company’s gross margin is expected to improve significantly, reaching 30% in 2025, while the net margin is projected to stabilize around 12% from 2026 onwards [4][13]

Investment Rating - The report maintains a "Buy" rating for the company [5][11] Core Views - The company is expected to see a significant increase in gross margin due to rising gold prices, with a forecasted gross margin of 30% in 2025 [3][10] - The adjustment in the franchise business is anticipated to reach its conclusion in 2026, which will alleviate revenue pressure [10] - The company has a strong dividend policy, with a historical payout ratio between 60%-100%, enhancing its investment appeal [10] Financial Forecasts - The adjusted earnings per share (EPS) forecasts for 2025-2027 are 1.02, 1.15, and 1.27 yuan respectively, down from previous estimates [3][11] - Revenue projections for 2023A, 2024A, 2025E, 2026E, and 2027E are 16,290 million, 13,891 million, 9,205 million, 10,033 million, and 11,092 million yuan respectively, with a notable decline in 2025 [4][13] - The net profit attributable to the parent company is forecasted to be 1,316 million, 1,010 million, 1,107 million, 1,243 million, and 1,379 million yuan for the years 2023A to 2027E [4][13] Valuation Metrics - The target price is set at 17.25 yuan based on a 15x PE ratio for 2026 [3][11] - The company’s current price-to-earnings (PE) ratio is 11.1, projected to decrease to 10.6 by 2027 [4][12] - The price-to-book (PB) ratio is currently at 2.3, expected to decline to 1.4 by 2027 [4][12]

投顾发展 | 投顾晨报 元月中阳收官在即，消费初显端倪 朝闻道 20260130 市场策略 元月中阳收官在即，2 月谨慎乐观 风格策略 周期轮动续力，消费初显端倪 行业策略 生猪：预期极度悲观，配置价值凸显 主题策略 食品饮料：赔率优化，胜率初显 风险提示 畜禽价格不及预期；畜禽疫病大规模爆发；原材料价格大幅波动；需求不及预期；食品安全、产业政策调 整等。 报告发布日期 2026 年 01 月 30 日 江韶军 执业证书编号：S0860525090001 jiangshaojun@orientsec.com.cn 021-63326320 于震荡中护慢牛，自中盘处取超额：朝闻 道 20260128 2026-01-27 震荡依旧，结构为王：朝闻道 20260126 2026-01-25 慢牛预期强化，把握中盘蓝筹：朝闻道 20260123 2026-01-21 有关分析师的申明，见本报告最后部分。其他重要信息披露见分析师申明之后部分，或请与您的投资代表联系。并请阅读本证券研究报告最后一页的免责申明。 ⚫ 临近月末再回首，1 月经历了先突破后盘整，中阳收官在即，依旧符合我们"横盘前 震荡，略有走强"的中期判断。 ...

Investment Rating - The report maintains a "Positive" investment rating for the electronic industry [5] Core Insights - The ongoing shortage of niche storage is expected to continue, with AI demand opening up incremental growth opportunities [2][8] - AI demand is anticipated to drive the need for niche storage, particularly in applications such as automotive, industrial, and security [7] - Domestic manufacturers are positioned competitively in the niche storage market and are likely to benefit from the supply constraints caused by international suppliers exiting this segment [7] Summary by Sections Investment Recommendations and Targets - Key investment targets include domestic storage chip design companies such as Zhaoyi Innovation, Puran, Jucheng, Dongxin, Beijing Junzheng, and Hengshuo [3][8] - Other relevant companies include domestic storage module manufacturers like Jiangbolong, Demingli, and Baiwei Storage, as well as semiconductor equipment firms such as Zhongwei, Jingzhida, and Beifang Huachuang [3][8] - Companies benefiting from storage technology iterations include Lanke Technology, Lianyun Technology, and Aojie Technology [3][8] Market Dynamics - The supply of niche storage products is being significantly reduced as major international suppliers focus on mainstream storage products, leading to a substantial contraction in supply [7] - For instance, the global MLC NAND Flash capacity is projected to decrease by 41.7% in 2026 due to supply shrinkage, which is expected to drive prices significantly higher [7] - Domestic firms are gaining market share in niche storage, with Zhaoyi Innovation holding approximately 18.5% of the NOR Flash market in 2024, ranking second globally [7]

Investment Rating - The industry investment rating is maintained as "Positive" [6] Core Insights - Concerns over geopolitical conflicts have increased, leading to a rise in Brent crude oil prices, which is expected to improve the oil service industry's outlook. Recent military actions by the U.S. against Venezuela and increased military presence near Iran have contributed to these concerns. Additionally, severe weather in the U.S. has impacted refining output. As a result, Brent crude oil prices have shown a sustained increase, and if this trend continues, capital expenditures in the industry are expected to marginally improve, enhancing the oil service sector's outlook [9] - Global oil and gas capital expenditures remain at low levels, indicating potential for upward recovery. Currently, the global active rig count is approximately 1,700-1,800, still below pre-2019 levels. In China, capital expenditures in the oil and gas sector have contracted due to oil prices and the end of the 14th Five-Year Plan, with expected year-on-year declines of 1.8% and 5.1% in 2024 and 2025, respectively. After several years of capital contraction, a recovery in industry expenditures is anticipated. Domestically, China's reliance on foreign oil and gas remains high, and a gradual recovery in capital expenditures is expected. Internationally, U.S. government policies are promoting oil and gas development, and the EIA predicts an increase in natural gas generation capacity in the coming years, suggesting a potential rebound in overseas oil service expenditure in 2026 [9] - The recovery in oil service sector sentiment takes time, emphasizing the importance of competitive companies. Due to the long construction cycles of oil service projects, owner companies often need to observe the sustainability of oil prices. Current geopolitical concerns have elevated oil prices and market expectations, but a recovery in oil service sentiment will require time. It is estimated that it will take at least six months for the positive effects of rising oil prices to be felt in the oil service sector. As downstream companies place greater emphasis on long-term partnerships with suppliers, companies with high competitiveness are expected to benefit more from the recovery [9]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The focus remains on the combination of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates), with significant advancements expected in their joint application [10][11] - The year 2026 is identified as a critical year for the combination of IO and ADC, with expectations for increased demand for ADCs, particularly in the context of various cancer treatments [11][41] Summary by Sections Section 1: Focus on Second-Generation IO and ADC - Merck's sac-TMT is a strategic focus, with 16 ongoing Phase III clinical trials, particularly in gynecological cancers [14][15] - AstraZeneca has 8 ADCs in clinical stages, with significant data readouts expected in 2026 [19][20] - Pfizer is advancing 4 Phase III clinical trials for its PD-1/VEGF dual antibody SSGJ-707, highlighting its strategic importance in oncology [26][27] - Johnson & Johnson aims to become the leading oncology company by 2030, focusing on multiple myeloma and various cancers [30] - Bristol-Myers Squibb (BMS) is advancing its PD-L1/VEGF dual antibody and oral CELMoD therapies, with significant data catalysts expected in 2026 [32][33] - Roche is focusing on breast cancer, with its oral SERD Giredestrant expected to be approved soon [37][38] Section 2: The Year of IO+ADC Combination - The combination of IO and ADC is seen as a key development direction, with various clinical trials underway [41] - The first-generation IO+ADC combinations are competitive, with sac-TMT emerging as a significant player [42] - The second-generation IO combined with chemotherapy is led by AK112, with multiple milestones expected in the coming years [47] - The second-generation IO combined with ADC is still in early exploration, with AstraZeneca leading the way [49] Section 3: Investment Recommendations and Targets - The report identifies several investment targets, including Kangfang Biotech, 3SBio, and others, highlighting their potential in the oncology sector [11][56]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The focus remains on the combination of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates), with significant advancements expected in their joint applications [10][11] - The year 2026 is identified as a critical year for the confirmation of IO combined with ADC, with expectations for increased demand for ADCs, particularly in the context of various cancer treatments [11][41] Summary by Sections Section 1: Focus on Second-Generation IO and ADC - Merck's sac-TMT is a strategic focus, with 16 ongoing Phase III clinical trials, particularly in gynecological tumors [14][15] - AstraZeneca has 8 ADCs in clinical stages, with significant data readouts expected in 2026 [19][20] - Pfizer is advancing 4 Phase III trials for its PD-1/VEGF dual antibody SSGJ-707, highlighting its strategic importance in oncology [26][27] - Johnson & Johnson aims to become the leading oncology company by 2030, focusing on multiple myeloma and other cancers [30] - Bristol-Myers Squibb (BMS) is advancing its PD-L1/VEGF dual antibody with multiple ongoing trials [32] Section 2: Confirming the Year of "IO+ADC" Combination - The combination of IO and ADC is seen as a key development direction, with various clinical trials underway [41] - The first-generation IO combined with ADC is competitive, with sac-TMT emerging as a significant player [42] - The second-generation IO combined with chemotherapy is led by AK112, with multiple milestones expected in the coming years [47] - The second-generation IO combined with ADC is still in early exploration, with AstraZeneca leading the way [49] Section 3: Investment Recommendations and Targets - The report identifies several investment targets, including Kangfang Biotech, 3SBio, and others, emphasizing their potential in the oncology sector [11][56]

Investment Rating - The report indicates a favorable outlook for mid-cap blue-chip stocks, particularly in cyclical sectors such as non-ferrous metals and chemicals, as well as manufacturing sectors like engineering machinery [6][16]. Core Insights - The anticipated changes are beneficial for mid-cap blue chips, with recent events catalyzing interest in cyclical industries and manufacturing, aligning with the market's shift towards a more balanced risk appetite [6][16]. - Key sectors to watch include non-ferrous metals, defense and military industry, and machinery equipment, with a noted strengthening trend in these areas [20][27]. Summary by Sections 1. Expected Changes Favoring Mid-Cap Blue Chips - Liquidity expectations have improved, leading to intensified trading activity, driven by rising optimism regarding interest rate cuts following the potential election of BlackRock's Riedel as Fed Chair, with a probability of 54% [9][11]. - Significant price increases in typical petrochemical products such as butadiene rubber, PX, PTA, and ethylene glycol have enhanced profitability expectations for refining companies [11][12]. - China's engineering machinery exports surged to USD 6.417 billion in December 2025, a 27.2% year-on-year increase, supported by more active participation in Belt and Road Initiative projects [12][15]. - The real estate market shows signs of recovery, particularly in major cities like Shanghai and Shenzhen, although the sustainability of this trend remains uncertain [15][27]. 2. Trading Dynamics - The report notes that while the overall market sentiment for large-cap stocks has declined, mid-cap and small-cap stocks exhibit stable short-term sentiment with decreasing medium-term uncertainty, suggesting potential for small-cap stocks to catch up [17][27]. - The report emphasizes the importance of monitoring trading behavior through asset volatility, indicating that changes in volatility reflect shifts in trading sentiment [17][20]. 3. Sector Rotation - The report highlights a strengthening trend in cyclical sectors related to mid-cap blue chips, particularly non-ferrous metals and basic chemicals, while the real estate sector shows weakening reversal signals [20][21][27]. - Short-term sentiment and medium-term uncertainty for non-ferrous metals, defense, and petrochemical sectors are both on the rise, indicating potential investment opportunities [23][26].

资产配置 | 定期报告 研究结论 报告发布日期 2026 年 01 月 28 日 | 郑月灵 | 执业证书编号：S0860525120003 | zhengyueling@orientsec.com.cn | | --- | --- | --- | | 021-63326320 | | | | 周仕盈 | 执业证书编号：S0860125060012 | zhoushiying@orientsec.com.cn | | 021-63326320 | | | | 美/日风险评价上升，贵金属及低风险特征 | 2026-01-26 | | --- | --- | | 权益占优：20260126 多资产配置周报 | | | CTA 策略仍强，指增和中性策略回暖： | 2026-01-22 | | 20260119 多策略及理财配置周报 | | | 风偏继续向中间集中：20260119 多资产配 | 2026-01-20 | | 置周报 | | | 以对冲配置思路应对美股/黄金"畏高" | 2026-01-19 | | 国内风险评价稳步下行，A 股/商品占优： | 2026-01-13 | | 20260112 多资产配 ...

1. Report Industry Investment Rating - Not mentioned in the provided content 2. Core Viewpoints - The impact of corporate foreign exchange settlement with banks on the capital market is slightly negative, while banks' foreign exchange settlement with the central bank significantly benefits the capital market. Attention should be paid to changes in the central bank's operations. Foreign exchange settlement can relieve the pressure of insufficient general deposits in banks and support certificate of deposit (CD) interest rates. The key influencing factors are the rhythm of banks' foreign exchange settlement with the central bank and changes in the central bank's investment scale [5][8][10]. - Last week, the bond market continued its recovery, with interest rates, especially long - term yields, dropping rapidly. The stock market sentiment was suppressed, and the central bank's net investment was large. Short - term trading was crowded initially, and then institutions shifted to long - term bonds, driving down long - term interest rates [5][41]. - In terms of high - frequency data, most production - side operating rates declined, demand - side indicators such as passenger car sales and real estate transactions were weak, and price trends were mixed [5][48][49]. 3. Summary by Directory 3.1 Bond Market Weekly Viewpoint - The impact of foreign exchange settlement on the capital market and CD interest rates is positive. Theoretically, as long as the proportion of banks' foreign exchange settlement with the central bank exceeds the legal deposit reserve ratio (currently 6.3%), foreign exchange settlement benefits the capital market. The actual data also shows a correlation where more foreign exchange settlement leads to a looser capital market [5][10][12]. - Foreign exchange settlement increases the general deposit scale of banks, relieves CD financing pressure, and thus supports CD interest rates [10]. 3.2 This Week's Focus in the Fixed - Income Market - This week, China will release January PMI. The US, Canada, and the Eurozone will also announce relevant economic data and central bank decisions [13][14]. - This week, the planned issuance of interest - rate bonds is expected to be around 609.3 billion yuan, including 439.3 billion yuan of local bonds and about 170 billion yuan of policy - bank bonds, with no planned issuance of national bonds [14][16]. 3.3 Review and Outlook of Interest - Rate Bonds 3.3.1 High - Level Open - Market Operations - Last week, the central bank's open - market operations had a high investment scale. Reverse repurchase investment first increased and then decreased, with a total investment of about 1.18 trillion yuan and a net investment of 229.5 billion yuan. MLF had a maturity of 200 billion yuan last week, and 900 billion yuan was invested, maintaining a high net investment in medium - and long - term liquidity. Considering the maturity of treasury deposits of 150 billion yuan, the total net investment in open - market operations last week was 979.5 billion yuan [20][22]. - The capital market fluctuated significantly, with capital interest rates mostly rising. Repurchase trading volume fluctuated, and overnight interest rates and DR007 both increased [22][23]. - CD prices adjusted according to the market, and secondary yields dropped rapidly. The net financing of CDs last week was - 116.9 billion yuan. The proportion of medium - term CDs increased, and long - term proportions decreased. Secondary yields of most CDs declined [29]. 3.3.2 Continued Sharp Decline in Bond Market Interest Rates - Last week, the bond market's recovery sentiment continued, with long - term yields dropping rapidly. The 10 - year treasury bond and CDB active bonds decreased by - 1.1bp and - 2.9bp respectively compared to the previous week. Most yields of interest - rate bonds at various maturities declined, except for the 1 - year treasury bond, which rebounded by about 4bp. The 10 - year CDB bond yield had the largest decline, about 4.2bp [5][41]. 3.4 High - Frequency Data - On the production side, most operating rates declined, including blast furnace, PTA, and asphalt operating rates, while the semi - steel tire operating rate increased. The daily average crude steel output in early January had a narrowing year - on - year decline [48]. - On the demand side, passenger car wholesale and retail sales continued to have a large year - on - year decline. The real estate market was weak, with a significant year - on - year decline in the transaction area of commercial housing. Export indices also decreased [48]. - In terms of prices, crude oil prices continued to rise, copper and aluminum prices diverged, and coal prices showed different trends. The prices of mid - stream building materials declined, and the prices of downstream consumer products such as vegetables and pork showed different changes [49].